Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.
Ellis PM, Leighl NB, Hirsh V, Reaume MN, Blais N, Wierzbicki R, Sadrolhefazi B, Gu Y, Liu D, Pilz K, Chu Q. Ellis PM, et al. Among authors: leighl nb. Clin Lung Cancer. 2015 Nov;16(6):457-65. doi: 10.1016/j.cllc.2015.05.010. Epub 2015 Jun 2. Clin Lung Cancer. 2015. PMID: 26100229 Clinical Trial.
A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer.
Leighl NB, Burkes RL, Dancey JE, Lopez PG, Higgins BP, David Walde PL, Rudinskas LC, Rahim YH, Rodgers A, Pond GR, Shepherd FA. Leighl NB, et al. Clin Lung Cancer. 2003 Sep;5(2):107-12. doi: 10.3816/CLC.2003.n.024. Clin Lung Cancer. 2003. PMID: 14596693 Clinical Trial.
Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
Leighl NB, Goss GD, Lopez PG, Burkes RL, Dancey JE, Rahim YH, Rudinskas LC, Pouliot JF, Rodgers A, Pond GR, Shepherd FA. Leighl NB, et al. Lung Cancer. 2006 Jun;52(3):327-32. doi: 10.1016/j.lungcan.2006.02.006. Epub 2006 Apr 4. Lung Cancer. 2006. PMID: 16597474 Clinical Trial.
Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group.
Ng R, Hasan B, Mittmann N, Florescu M, Shepherd FA, Ding K, Butts CA, Cormier Y, Darling G, Goss GD, Inculet R, Seymour L, Winton TL, Evans WK, Leighl NB; Working Group on Economic Analysis; Lung Disease Site Group; National Cancer Institute of Canada Clinical Trials Group. Ng R, et al. Among authors: leighl nb. J Clin Oncol. 2007 Jun 1;25(16):2256-61. doi: 10.1200/JCO.2006.09.4342. J Clin Oncol. 2007. PMID: 17538170 Clinical Trial.
Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, Whitehead M, Spaans JN, Graham BC, Goss GD; National Cancer Institute of Canada Clinical Trials Group. Asmis TR, et al. Among authors: leighl nb. J Clin Oncol. 2008 Jan 1;26(1):54-9. doi: 10.1200/JCO.2007.12.8322. J Clin Oncol. 2008. PMID: 18165640 Clinical Trial.
325 results